$TRON For those just catching up on a Monday morning, the quarterly report, ending 10/31/18, was filed yesterday on otcmarkets.
https://backend.otcmarkets.com/otcapi/company...04/content
While most of what was disclosed was to be expected, there were a few tidbits that are worth noting.
1) The most exciting element was the confirmation of the intent to pursue future acquisitions. It was mentioned even prior to the Flagship arrangement that Toron was not just looking for InMed as a one-and-done deal, but instead, as one of a "series of acquisitions". In the quotes below, from the quarterly report, it is again reiterated. And as speculative, and only speculative, drawing of conclusions, the board of director expansion and integration comes to mind. If InMed was already operating successfully, and then Toron came along, adding Toron's CEO Morentin and the Toron team, then InMed would now have even more executive manpower. So unless there was much more to come, either through expansion of InMed and/or separate acquisitions, there would be little reason to keep beefing up the board, especially seeing the cumulative experience already in place that could easily operate and tighten up InMed with no extra additions in executive or advisory personnel.
"Additionally, Toron is acquiring 3 operational hospitals and 9 senior care facilities in Alabama and Georgia pursuant to our acquisition of the InMed Group. It is Toron’s intent" to continue to pursue additional acquisitions in the medical related markets.
2) The second element of note, was the disclosure of the 81 million shares. While to date, there has been zero dilution to the 299M float in approx 2yrs, coupled with a massive reduction in authorized shares, there was an O/S increase, which was found to be repayment to the owner-corporation of the entity that merged into Toron with its iMedScan subsidiary. The 81 million shares went to Patienttrac in full satisfaction of advanced expenses.
So we are now seeing the restricted end of the O/S as inside ownership, and each being held by companies, rather than in individual names. Companies are more likely to hold long term positions than are individuals. Also, companies invested in such a manner know that holding may result in Toron becoming an acquisition target itself over time by even larger healthcare institutions, which would result in share buyouts by the acquiring company. What is also of note, is that the shares owned by insiders are part of the common shares of the O/S, rather than preferred shares. This means that the O/S has already factored in their ownership, and that those shares will not be preferred shares in need of conversion into the O/S. Additionally, preferred shares are protected in the case of a reverse split and don't lose value, while common shares are subject to any direction the split takes the stock. Seeing as the insider shares are common shares rather than preferred shares, both insiders and investors are sailing on the same ship.
3) The third and final item that became apparent, was the iMedScan potential for dual-end revenues. iMedScan will serve to increase revenues for Toron and InMed via insurance and payment issues that were previously hard to navigate for the insured and the insurer,and it will also serve as a revenue generating stream from what I can best deduce forward as software sales and medical technology. So currently in the pocket, we have InMed, iMedscan improvements to InMed, with future healthcare acquisitions to come, and medical technology sales in tow.
" iMedScan provides ease of use for patients by simplifying their
check-in registration process, while at the same time reducing the healthcare providers’ administrative expenses and lost revenues by eliminating insurance rejections, denials or any results from erroneous or incomplete patient information verification. iMedScan’s revenue model presents an up-front income boost. However, its long term financial strength
is derived from its tremendous back-end revenue stream"
8-k by Sterling Issuer Services should be arriving shortly, with no exact time frame provided as of yet. Also to look forward to, would be the transfer of state and federal paperwork between Toron and InMed, which has already been filed and submitted, and is expected to be completed within range of 12/21/18. Again, that is not a date set in stone, as no one outside of the govt can really tell you the exact date someone inside the govt will finish their end of the paperwork. It's done when it's done. And finally, auditors are being selected so as to bring Toron forward as a fully reporting, SEC compliant company. Everything is falling into place.
https://backend.otcmarkets.com/otcapi/company...04/content
While most of what was disclosed was to be expected, there were a few tidbits that are worth noting.
1) The most exciting element was the confirmation of the intent to pursue future acquisitions. It was mentioned even prior to the Flagship arrangement that Toron was not just looking for InMed as a one-and-done deal, but instead, as one of a "series of acquisitions". In the quotes below, from the quarterly report, it is again reiterated. And as speculative, and only speculative, drawing of conclusions, the board of director expansion and integration comes to mind. If InMed was already operating successfully, and then Toron came along, adding Toron's CEO Morentin and the Toron team, then InMed would now have even more executive manpower. So unless there was much more to come, either through expansion of InMed and/or separate acquisitions, there would be little reason to keep beefing up the board, especially seeing the cumulative experience already in place that could easily operate and tighten up InMed with no extra additions in executive or advisory personnel.
"Additionally, Toron is acquiring 3 operational hospitals and 9 senior care facilities in Alabama and Georgia pursuant to our acquisition of the InMed Group. It is Toron’s intent" to continue to pursue additional acquisitions in the medical related markets.
2) The second element of note, was the disclosure of the 81 million shares. While to date, there has been zero dilution to the 299M float in approx 2yrs, coupled with a massive reduction in authorized shares, there was an O/S increase, which was found to be repayment to the owner-corporation of the entity that merged into Toron with its iMedScan subsidiary. The 81 million shares went to Patienttrac in full satisfaction of advanced expenses.
So we are now seeing the restricted end of the O/S as inside ownership, and each being held by companies, rather than in individual names. Companies are more likely to hold long term positions than are individuals. Also, companies invested in such a manner know that holding may result in Toron becoming an acquisition target itself over time by even larger healthcare institutions, which would result in share buyouts by the acquiring company. What is also of note, is that the shares owned by insiders are part of the common shares of the O/S, rather than preferred shares. This means that the O/S has already factored in their ownership, and that those shares will not be preferred shares in need of conversion into the O/S. Additionally, preferred shares are protected in the case of a reverse split and don't lose value, while common shares are subject to any direction the split takes the stock. Seeing as the insider shares are common shares rather than preferred shares, both insiders and investors are sailing on the same ship.
3) The third and final item that became apparent, was the iMedScan potential for dual-end revenues. iMedScan will serve to increase revenues for Toron and InMed via insurance and payment issues that were previously hard to navigate for the insured and the insurer,and it will also serve as a revenue generating stream from what I can best deduce forward as software sales and medical technology. So currently in the pocket, we have InMed, iMedscan improvements to InMed, with future healthcare acquisitions to come, and medical technology sales in tow.
" iMedScan provides ease of use for patients by simplifying their
check-in registration process, while at the same time reducing the healthcare providers’ administrative expenses and lost revenues by eliminating insurance rejections, denials or any results from erroneous or incomplete patient information verification. iMedScan’s revenue model presents an up-front income boost. However, its long term financial strength
is derived from its tremendous back-end revenue stream"
8-k by Sterling Issuer Services should be arriving shortly, with no exact time frame provided as of yet. Also to look forward to, would be the transfer of state and federal paperwork between Toron and InMed, which has already been filed and submitted, and is expected to be completed within range of 12/21/18. Again, that is not a date set in stone, as no one outside of the govt can really tell you the exact date someone inside the govt will finish their end of the paperwork. It's done when it's done. And finally, auditors are being selected so as to bring Toron forward as a fully reporting, SEC compliant company. Everything is falling into place.
ALL THINGS MOBILE ANALYTIC INC. (ATMH) Stock Research Links
Do your own DD. Assume everyone here is either an amateur trader/investor or a paid interest such as a compensated pumper/basher. My posts are strictly for entertainment purposes. I am not on Wall St., do not work for a group, and only get paid when my personal investments materialize. I am only responsible for my own gains and losses; no one is to blame for my mistakes or for any advice taken from postings; likewise, I am not to blame for any advice you take of mine, regardless of gains or losses from doing so. Good luck to all; may you live long and prosper greatly.
